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The sulphonylurea drug, glimepiride, stimulates release of
glycosylphosphatidylinositol-anchored plasma-membrane proteins
from 3T3 adipocytes
Gunter MULLER,t Elizabeth Ann DEAREY* and Jurgen PUNTER
Hoechst Aktiengesellschaft Frankfurt am Main Pharmaceutical Research Division SBU Metabolism, D-6230 Frankfurt 80, Germany
Sulphonylurea drugs stimulate glucose transport and metabol- [14C]inositol demonstrates that inositol is retained in the major
ism in muscle and fat cells in vitro. The molecular basis for the portion of released lipoprotein lipase and cAMP-binding
insulin-mimetic extrapancreatic effects of these oral antidiabetic ectoprotein. The identification of inositol phosphate after de-
therapeutic agents is unknown at present. Here we demonstrate amination of these proteins with nitrous acid suggests cleavage
that incubation of 3T3 adipocytes with the novel sulphonylurea, of their GPI membrane anchor by a GPI-specific phospholipase
glimepiride, causes a time- and concentration-dependent release C. However, after longer incubation with glimepiride the
of the glycosylphosphatidylinositol (GPI)-anchored ecto- amount of soluble versions of the GPI-proteins lacking inositol
proteins, 5'-nucleotidase, lipoprotein lipase and a 62 kDa cyclic and anti-CRD immunoreactivity increases, which may be
AMP (cAMP)-binding protein from the plasma membrane into caused by additional drug-stimulated hydrolytic events within
the culture medium. The change in the localization is their GPI structure or C-termini. Since insulin also stimulates
accompanied by conversion of the membrane-anchored membrane release of these GPI-modified proteins, and in
amphiphilic proteins into their soluble hydrophilic versions, as combination with glimepiride in a synergistic manner,
judged by pulse-chase experiments and Triton X- 114 partition- sulphonylurea drugs may exert their peripheral actions in adi-
ing, and by appearance of anti-cross-reacting determinant pose tissue by using (part of) the insulin postreceptor signalling
(CRD) immunoreactivity of the released proteins as shown by cascade at the step of activation of a GPI-specific phospho-
Western blotting. Metabolic labelling of cells with myo- lipase C.
INTRODUCTION control or a direct site of action of the drug at the muscle or fat
cell.
For several decades sulphonylurea compounds have been widely To discriminate between direct sites of action of sulphonylurea
used as hypoglycaemic agents in the treatment of type II or non- drugs and effects mediated via insulin, experiments in vitro with
insulin-dependent diabetes mellitus. These drugs have been isolated cell preparations are of advantage. During the last two
shown to act at both pancreatic and extrapancreatic loci [for a decades a large body of evidence has accumulated that
review see Boyd (1988) and Gerich (1989)]. The initial effects of sulphonylurea agents enhance basal and insulin-stimulated glu-
sulphonylurea administration appear to arise from acute stimu- cose transport and metabolism in both human and animal
lation of the rate of insulin release from the pancreas (Yalow et muscle (Gibson et al., 1980; Rogers et al., 1987; Wang et al.,
al., 1960). 1987, 1989) and fat cells (Jacobs et al., 1989; Farese et al., 1991)
Recently, attention has been focused on the extrapancreatic in vitro. However, the molecular mechanisms for these
actions of sulphonylureas, since prolonged drug studies with stimulatory effects of the drugs are unknown. The increased
diabetic patients have demonstrated that plasma insulin levels insulin sensitivity in vitro may be caused by a higher number,
often return to pretreatment levels even though the binding affinity or tyrosine kinase activity of the insulin receptor.
sulphonylurea-induced hypoglycaemic effect persists (Simonson However, the evidence available strongly points toward a post-
et al., 1970, 1984; Lebovitz et al., 1977; Greenfield et al., 1982; receptor effect (Maloff and Lockwood, 1981; Davidson and
Kolterman et al., 1984; Mandarino and Gerich, 1984; Ward Sladen, 1987; Jacobs et al., 1987; Bak et al., 1989), which would
et al. 1985). Thus these compounds possess the interesting also explain the stimulation of glucose transport in the absence
additional property of increasing glucose uptake and utilization of insulin.
in peripheral tissues after prolonged exposure (Feldman and The activation of protein kinase C via a sulphonylurea-induced
Lebovitz, 1971). Similar findings have been reported in studies increase in diacylglycerol during stimulation of basal glucose
with animals exposed for prolonged intervals to various transport in cultured myocytes and adipocytes has been suggested
sulphonylurea agents (Caren and Corbo, 1957; Putnam et al., (Rogers et al., 1987; Farese et al., 1991; Davidson et al., 1991).
1981; Hirshman and Horton, 1990). It remains a matter of One potential source of diacylglycerol may reside in glucosyl-
debate as to whether the improved insulin sensitivity observed phosphatidylinositol (GPI) membrane anchors of certain plasma-
during studies in vivo is due to improved overall metabolic membrane ectoproteins, since their metabolism in response to
Abbreviations used: cAMP, cyclic AMP; DMEM, Dulbecco's minimal essential medium; FCS, fetal calf serum; IBMX, 3-isobutyl-1-methylxanthine; LPL,
lipoprotein lipase; DTT, dithiothreitol; PMSF, phenylmethanesulphonyl fluoride; CRD, cross-reacting determinant; PI, phosphatidylinositol; GPI,
glycosylphosphatidylinositol; PI/GPI-PLC, PI/GPI-specific phospholipase C; GPI-protein, protein that is synthesized with a GPI modification, irrespective
of whether this structure is preserved or not (e.g. after lipolytic cleavage).
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insulin accompanied by release of the protein moiety from the
cell surface of adipocytes and myocytes has been observed (Chan
et al., 1988; Romero et al., 1988; Lisanti et al., 1989) and
correlated with stimulation of glucose metabolism (Romero et
al., 1988). Furthermore, the cleavage products of structurally
related free GPI lipids, diacylglycerol and polar phosphoinositol-
glycan headgroups, activate glucose transport in isolated rat
adipocytes presumably by a two-step mechanism (Obermaier-
Kusser et al., 1989; Vogt et al., 1990).
Therefore we have studied whether degradation of the GPI
membrane anchor and membrane release of GPI-proteins are
stimulated by sulphonylurea drugs.
MATERIALS AND METHODS
Materials
myo-[l-14C]Inositol (55 mCi/mmol), glycerol tri[9,10(n)-3H]
oleate (0.6 Ci/mmol), [2,8-3H]cAMP (45 Ci/mmol), myo-L-
[U-14C]inositol 1-phosphate (50 mCi/mmol) and goat anti-
(rabbit IgG) coupled to peroxidase (affinity-purified) were
bought from Amersham-Buchler (Braunschweig, Germany);
8-N3-[32P]cAMP (20 Ci/mmol), 8-N3-[3H]cAMP (20 Ci/mmol),
L-[U-14C]leucine (300 mCi/mmol) and L-[4,5-3H(n)]leucine
(5 Ci/mmol) were from ICN (Eschwege, Germany); [G-3H]AMP
(25 Ci/mmol) and EN3HANCE was purchased from
DuPont-New England Nuclear (Dreieich, Germany); 3T3
fibroblasts clone A31 were obtained from the American Type
Culture Collection (CCL 163). Phenylmethanesulphonyl fluoride
(PMSF), 3-isobutyl-1-methylxanthine (IBMX), dexamethasone,
defatted BSA and phosphatidylcholine were provided from
Sigma (Deisenhofen, Germany); Dulbecco's minimal essential
medium (DMEM), Hanks buffer, antibiotics and sera for cell
culture, pertussis and cholera toxin were from Gibco-BRL
(Eggenstein-Leopoldshafen, Germany); Protein A-Sepharose
and Nf-(2-aminoethyl)-cAMP-Sepharose were purchased from
Pharmacia (Freiburg, Germany); PI-specific phospholipase C
(PI-PLC) (Bacillus cereus), cycloheximide, leupeptin and antipain
hydrochloride were provided from Boehringer (Mannheim,
Germany); pepstatin A was bought from Fluka (Neu-Ulm,
Germany); a2-macroglobulin, aminoethylbenzylsulphonyl-
fluoride, silica gel Si6O t.l.c. plates and all other chemicals
(highest purity available) were obtained from Merck, Darmstadt,
Germany. A polyclonal rabbit antiserum against purified
human milk lipoprotein lipase (LPL) was kindly provided by
Dr. C.-S. Wang (Oklahoma, OK, U.S.A.). Polyclonal anti-[cross-
reacting determinant (CRD)] antibodies raised against purified
soluble variant surface glycoprotein from MITat 1.2 in New
Zealand White rabbits were a kind gift from P. Overath,
Tiibingen, Germany. Semi-synthetic human insulin and
glimepiride were prepared by the Pharma Synthesis Department
of Hoechst Aktiengesellschaft, Frankfurt. Glimepiride was dis-
solved in 25 mM Hepes/KOH (pH 7.4) to give a 2 mM stock
solution made daily.
Cell culture
Cell culture was performed according to published procedures
(Chan et al., 1988; Harrison et al., 1991a, b). Briefly, 3T3
fibroblasts were seeded at a density of 60 cells/mm2, grown in
DMEM containing 25 mM glucose, 10 % fetal calf serum (FCS),
50 units/ml penicillin and 50 ,ug/ml streptomycin sulphate (20 ml
of medium per culture flask or 1.5 ml per well of a 24-well culture
plate) and maintained in a 10% CO2-humidified atmosphere at
37 'C. The medium was changed every 2-3 days. Several days
after the cells had achieved confluence, differentiation was
induced with the same volume of DMEM containing 10% FCS,
10 jug/ml insulin, 0.25 ,uM dexamethasone, 0.5 mM IBMX,
50 units/ml penicillin and 50 ,tg/ml streptomycin sulphate. After
2 days, the cells were incubated with the same medium without
IBMX and dexamethasone for 2 additional days. Subsequently
the cells were maintained in DMEM containing 100 FCS and
antibiotics. The medium was changed at intervals of 2-3 days.
Cells were used 5-10 days after the induction of differentiation.
About 80-90% of these cells expressed the adipocyte phenotype.
Living cell numbers were determined by counting the Trypan
Blue-excluding cells harvested after trypsin treatment (0.1%
trypsin for 10 min at 30 'C) of the cell monolayers by using a
haemocytometer.
Cell membrane preparation
Plasma membranes from 3T3 adipocytes were prepared as
described by Simpson et al. (1983) with modifications according
to James et al. (1989) and Clancy and Czech (1990). Briefly, cells
were grown in culture flasks and incubated in 20 ml of high-
glucose (25 mM) DMEM containing 10% FCS and antibiotics
with or without agent as indicated at 37 °C for the times indicated.
Subsequently, the cells were washed once with 25 ml of room
temperature phosphate-buffered saline/ 1 mM EDTA/250 mM
sucrose and twice with 15 ml of buffer 1 (25 mM Hepes, 1 mM
EDTA, 1 mM PMSF, 250 mM sucrose, pH 7.4). The monolayer
from one flask was scraped into 50 ml of ice-cold buffer I
supplemented with 0.1 mM PMSF and immediately homo-
genized with 10 strokes of a motor-driven (750 rev./min) Teflon
pestle in a 60 ml glass homogenizer (Braun, Melsungen,
Germany). The homogenate was centrifuged (16000 g, 20 min,
4 °C). The pellet was resuspended in 10 ml of buffer 11 (20 mM
Hepes, 1 mM EDTA, pH 7.4) with a Dounce homogenizer and
layered on to 20 ml of a sucrose cushion (1.12 M sucrose in
buffer II) and centrifuged (100000 g, 1 h, 4 'C). Plasma
membranes were recovered from the top of the sucrose cushion,
resuspended in 30 ml of buffer II and collected by centrifugation
(30000 g, 30 min, 4 °C). The plasma membranes were washed by
repetition of the last centrifugation and finally resuspended in
buffer II containing 1 mM PMSF at about 2 mg of protein/ml.
Metabolic labelling
The labelling was performed in culture flasks as described by
Chan et al. (1988) with modifications. Cells were washed with
20 ml of Hanks' buffer (pH 7.4), 0.5 % BSA and incubated with
250,uCi of myo-[14C]inositol in 20 ml ofDMEM containing 10%
FCS, 5 mM glucose, 0.5 % BSA, 50 units/ml penicillin and
50,g/ml streptomycin sulphate for 14 h in 5% CO2/95 % air at
37 'C. For labelling with radioactive leucine the cells were
incubated with 0.75 mCi [14C]leucine or 0.1 mCi [3H]leucine in
leucine-free DMEM (see above). Subsequently, the cells were
washed three times with 10 ml of Hanks' buffer (pH 7.4)/0.5 Go
BSA/1 mM myo-inositol or 1OmM leucine and then for in-
cubation with glimepiride (chase) supplemented with 20 ml of
high-glucose DMEM/10 % FCS/0.5 % BSA/0.1 mM myo-in-
ositol or leucine/50 units/ml penicillin/50 g/ml streptomycin
sulphate/I mM IBMX/0.1 mM PMSF.
Photoaffinity labelling
This was carried out by a method adapted from one used for
yeast cells (Muller and Bandlow, 1991a). The labelling was
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performed in 24-well culture plates. Cells were washed twice with
2 ml of DMEM containing 1 % BSA, 1 mM EDTA, 100 mM
NaCl and without glucose, serum and antibiotics. To each
monolayer, 10 ,tCi 8-N3-[32P]cAMP (0.5 nmol) or 2 uCi 8-N3-
[3H]cAMP in 0.5 ml of phosphate-buffered saline/250 mM
sucrose/i mM EDTA/50 mM KCl/10 mM MgCl2/2 mM
MnCl2/1mM IBMX/1 mM dithiothreitol (DTT)/1 mM AMP/
0.1 mM PMSF was added. The wells were incubated for
30 min at 4 °C and then irradiated with u.v. light at 254 nm
(8000 _tW/cm2) at a distance of 2 cm for 2 min. Subsequently,
the cells were washed twice with 2 ml of the same buffer
containing 1 mM unlabelled cAMP instead of 8-N3-[32P]cAMP
and then for incubation with glimepiride (chase) supplemented
with 1 ml of high-glucose DMEM, 0.1 mM cAMP, 10% FCS,
0.5 % BSA, 50 units/ml penicillin, 50 ,tg/ml streptomycin
sulphate, 1 mM IBMX and 0.1 mM PMSF.
Triton X-114 partitioning
This was carried as described by Bordier (1981) with the following
modifications: 50,1 of the incubation mixture was added
to 1 ml ice-cold Triton X-1 14 (2 %) in 25 mM Tris/HCl (pH 7.4)/
144 mM NaCl. The mixture was layered on to a cushion
of 0.4 ml 250 mM sucrose/25 mM Tris/HCl (pH 7.4) on ice.
Phase separation was induced by warming up to 37 °C and
centrifugation (Microfuge, 2 min). The detergent phase was re-
extracted twice. The aqueous phases were pooled.
Immunoprecipitation
Immunoprecipitation was performed according to Muller and
Bandlow (1991b) with the following modifications. Medium
samples (200,u of a supernatant, Microfuge, 2 min) were passed
through a Millex GV 0.2 uM filter, subsequently precipitated
with 100% (v/v) trichloroacetic acid and dissolved in 50,ul of
10 mM Tris/HCl (pH 8.0)/i mM EDTA/2 % (w/v) SDS. After
being heated at 95 °C for 5 min and centrifugation (Microfuge,
5 min), the supernatant was supplemented with 1 ml of
immunoprecipitation buffer (10 mM Tris/HCl, pH 8.0, 150 mM
NaCl, 0.05 % Triton X-100). Membrane samples (50,g protein
in buffer II) were adjusted to 2 % SDS and processed as described
above. Then 10#1 of a 1:250 dilution of a polyclonal rabbit
antiserum against human milk LPL was added. After 12 h at
4 °C followed by addition of 50,l of Protein A-Sepharose, the
incubation was continued for 2 h. The immunoprecipitates were
collected by centrifugation, washed twice with immuno-
precipitation buffer, twice with buffer not containing Triton
X-I00 and finally dissolved in 60 mM Tris/HCl (pH 6.8)/2%
SDS/5% 2-mercaptoethanol/10% (v/v) glycine and analysed
by SDS/PAGE and fluorography.
For immunoprecipitation with anti-CRD antibodies, cAMP
affinity-purified samples were precipitated with poly(ethylene
glycol) 4000 (see below), washed and dissolved in 1 ml of 20 mM
Tris/HCl (pH 7.5)/0.5 mM EDTA/I mM PMSF/O.1 % SDS.
Anti-LPL immunoprecipitates (material adsorbed to Protein
A-Sepharose beads obtained after centrifugation, see above) and
trichloroacetic acid precipitates (obtained after centrifugation
and two acetone washes) were supplemented with 50,l of 60 mM
Tris/HCl (pH 6.8)/0.5 mM EDTA/ 1 mM PMSF/2% SDS/2%
mercaptoethanol, incubated at 95 °C for 5 min and centrifuged
(10000 g, 2 min). The pellet was washed three times with
immunoprecipitation buffer and the combined supernatants were
adjusted to 1 ml with immunoprecipitation buffer. The samples
for 1 h at 4°C and then with 25,1 goat anti-(rabbit IgG)
antibodies coupled to agarose for 30 min at 4 °C with gentle
shaking. After centrifugation (10000 g, 2 min), the pellet was
washed and processed as described above. Under these conditions
the anti-CRD antibodies quantitatively immunoprecipitate Pl-
PLC-cleaved cAMP-binding protein and LPL (see Figure 1).
Affinity purffication
This was carried out as described (Muller et al., 1992) with the
following modifications: 200,ug of solubilized plasma-membrane
protein (25 mM Mops/KOH, pH 7.0, 150 mM NaCl, 0.5 mM
EDTA, 0.5 mM DTT, 0.5% octyl glucoside) or 250 pl of culture
medium were applied to a 2 ml column of N6-(2-aminoethyl)-
cAMP-Sepharose. The column was washed five times with
25 mM Mops/KOH (pH 7.2)/100 mM sodium citrate/
150 mM NaCl/2 mM DTT/l mM MgCl2/10% glycerol/I mg/
ml BSA/ 1 mM IBMX and eluted with 2 ml of the same buffer
containing 10 mM cAMP. The initial 250,l of the eluate was
desalted by centrifugation through a 1 ml column of Sephadex
G-25 and then precipitated with 5% poly(ethylene glycol) 4000.
The precipitates were dissolved in 20 mM Mops/KOH
(pH 7.2)/0.5 mM EDTA/0.I mM PMSF/0.5 % octyl glucoside.
Digestion with PLC
The cell monolayer of one well (per 24-well plate) was washed
with DMEM and then incubated with 0.5 ml DMEM containing
0.05 or 0.25 unit PI-PLC (Bacillus cereus) (1 unit is defined as
5, mol bovine acetylcholinesterase cleaved/min), 120 mM NaCl,
2 mM EDTA, 5 mM DTT, 0.005% Triton X-I00 and 0.1 mg/ml
phosphatidylcholine for 2 h at 37 'C.
T.I.c.
The samples were concentrated by freeze-drying, suspended in
water, applied to a silica gel Si6O t.l.c. plate and developed twice
in pyridine/ethyl acetate/acetic acid/water (5:5:1:3, by vol.).
Radioactive spots were visualized by autoradiography.
Enzyme assays
LPL activity was assayed as described (Nilsson-Ehle and Schotz,
1976) with a concentrated anhydrous emulsion of [3H]glycerol
tri[9, I0(n)-3H]oleate in glycerol stabilized with phosphatidyl-
choline as substrate. The final concentrations were triolein
(7.5 mM), phosphatidylcholine (0.6 mM), BSA (0.75%, w/v),
glycerol (10%) and FCS (7.5 %, v/v) in 50 mM Hepes/KOH
(pH 7.8). Incubations were carried out in a total volume of 250,1
for 20 min at 37 'C. The activity of 5'-nucleotidase was assayed
as described by Avruch and Wallach (1971) with minor
modifications. Briefly, the test was performed in a total volume
of 1 ml containing 100 mM Tris/HCl (pH 7.4), 20 mM MgCl2
and 0.5 mM [3H]AMP (100 nCi) for 30 min at 37 'C. The reaction
was stopped by the addition of 250 mM ZnSO4. Unhydrolysed
AMP and protein were precipitated by the addition of 250,l of
0.3 M Ba(OH)2. The adenosine remaining in solution after
centrifugation of the sample (Microfuge, 2 min) was counted for
radioactivity in 10 ml of scintillation cocktail (Zinsser 361).
Adenylate cyclase was measured as described by Salomon et al.
(1974). Lactate dehydrogenase was assayed by a standard
spectrophotometric assay (Wroblewski and LaDue, 1955). Mg2+-
ATPase was determined as in Hidalgo et al. (1983).
Succinate: cytochrome c oxidoreductase assay was carried out as
were incubated with 5, 1 anti-CRD antiserum (1:500 dilution) described in Lang et al. (1977).
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cAMP binding
This was measured by the methods of Pomerantz et al. (1975),
Rodel et al. (1985) and Muller and Bandlow (1989) with
modifications. Medium or membranes were precipitated with
8 % poly(ethylene glycol) (15 min, 4 °C; Microfuge, 5 min) and
dissolved in binding buffer (25 mM Mes, pH 6.2, 100 mM KCI,
5mM MgCl2, 1 mM MnCl2, 0.5 mM EDTA, 0.2mM DTT,
1 mM IBMX, 0.1 mM PMSF, 0.1 mM AMP, 0.2% octyl glu-
coside). About 100 jtg of protein was incubated with 100 nCi
[3H]cAMP (about 2 nmol) in the presence or absence of 0.8 mM
cAMP in a total volume of 250,ul for 5 min at 4 'C. After
addition of 0.5 ml ice-cold saturated (NH4)2SO4, the sample was
rapidly filtered through a nitrocellulose filter (Millipore, HAWP,
0.45 uM) under vacuum. The filter was washed three times with
5 ml of washing buffer (25 mM Mes, pH 6.2, 100 mM KCI,
5 mM MgCl2, 1mM MnCl2, 0.5mM EDTA, 1 mM IBMX,
0.1 mM PMSF, 1 mM AMP), dried at 70 'C and counted for
radioactivity in 5 ml of scintillation cocktail (Zinsser 361).
Specific cAMP binding was calculated as the difference between
radioactivity measured in the absence and presence of 0.8 mM
cAMP.
(Figure lb) into their soluble hydrophilic versions as judged by
centrifugation and Triton X-1 14 partitioning which correlated
with the appearance of anti-CRD immunoreactivity of the
solubilized GPI-proteins as demonstrated by immuno-
precipitation with anti-CRD antibodies. The epitope recognized
by anti-CRD antibodies primarily consists of the inositol 1,2-
cyclic monophosphate residue generated by PLC cleavage of the
GPI moiety (Zamze et al., 1988) and thus was available only in the
lipolytically cleaved (lanes 18, 20, 22 and 24) but not in the intact
form of LPL and cAMP-binding ectoprotein (lanes 13-17, 19, 21
and 23). The immunoprecipitation of the radiolabelled PI-PLC-
cleaved GPI-proteins by anti-CRD serum was nearly quan-
titative. Furthermore, up to 75% of 5'-nucleotidase activity was
released from plasma-membrane vesicles after treatment with
bacterial PI-PLC in a concentration-dependent manner (results
not shown).
We next studied whether treatment of 3T3 adipocytes with the
novel sulphonylurea compound, glimepiride, causes an increase
(a)
Miscellaneous procedures
Nitrous acid deamination (Muller and Bandlow, 1991a), ex-
traction from silica gel, elution of proteins from polyacrylamide
gels (Muller et al., 1992), SDS/PAGE using 15% separating and
5% stacking gels in the presence of urea (Laemmli, 1970; Muller
and Zimmermann, 1987), fluorography using EN3HANCE
(Chamberlain, 1989), densitometry with an LKB densitometer,
protein determination (Popov et al., 1975; Bradford, 1976) and
liquid-scintillation counting using scintillation cocktail ASC II
(Amersham-Buchler) were performed according to published
procedures.
RESULTS
3T3-Ll adipocytes contain a number of GPI-anchored plasma-
membrane proteins (Chan et al., 1988; Lisanti et al., 1989).
Release of these ectoproteins from the plasma membrane into
the culture medium by removal of their GPI membrane anchor
has been observed after short-term incubation with insulin (see
the Discussion). We asked whether sulphonylurea drugs, which
exert certain insulin-like effects on these cells, also mimic
membrane release of GPI-proteins.
We studied three proteins for which anchorage at the plasma
membrane by a GPI structure has been established, LPL (Chan
et al., 1988), 5'-nucleotidase (Low and Finean, 1978) and a novel
cAMP-binding ectoprotein (62 kDa). This protein can be
detected by photoaffinity labelling with the membrane-imper-
meable 8-N3-cAMP of intact adipocytes isolated by collagenase
digestion under strictly controlled conditions or of 3T3
adipocytes cultured as monolayers but without trypsin treatment
(Muller and Bandlow, 1991c; G. Muller and S. Wied, un-
published work). The presence of a GPI membrane anchor has
been demonstrated by its metabolic labelling with typical
constituents of this structure. A similar cAMP-binding protein
has been identified in the yeast Saccharomyces cerevisiae (Muller
and Bandlow, 1991a,b).
In addition, the anchorage to the membrane by a GPI moiety
of the three proteins in the 3T3 adipocytes from the subclone
used in this study was confirmed by incubation of intact
adipocytes with bacterial PI-PLC (Figure 1). This caused a
concentration-dependent conversion of the total membrane-
bound amphiphilic LPL (Figure la) and cAMP-binding protein
H
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Figure 1 Susceptibility of GPI-proteins of 3T3 adipocytes to digestion with
bacterial PI-PLC
3T3 adipocytes were metabolically labelled with myo_[14C]inositol, incubated with different
amounts of PI-PLC (Bacillus cereus) and then scraped from the plate. One-half of the total
incubation mixture (culture medium and cells) was subjected to centrifugation (150000 ,1 h),
the other half to Triton X-114 partitioning. The membrane (m) and soluble (s) fractions or
detergent (d) and aqueous (a) phases were analysed by immunoprecipitation with anti-LPL
serum (a, LPL) and cAMP-Sepharose affinity purification (b, cAMP-binding protein). One-half
of the immunoprecipitates and affinity-purified material was subjected directly to SDS/PAGE and
fluorography (upper gels, total), the other half was immunoprecipitated with anti-CRD antibodies
and then analysed by SDS/PAGE and fluorography (lower gels, anti-CRD). Immunoprecipitated
metabolically labelled LPL and N3-[32P]cAMP-photoaffinity-labelled cAMP-binding protein from
adipocyte homogenate are shown as marker (M) on the margins.
.
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Figure 2 Glimepiride-induced increase in the activity of GPI-proteins in the culture medium
(a) Time course. 3T3 adipocytes were incubated in the absence (curve B) or presence of glimepiride (50 ,uM) without (curve A) or with (curve C) cycloheximide (150 ,ug/ml). After different times,
portions of the culture medium were withdrawn and the activities of 5'-nucleotidase and LPL as well as cAMP-binding per ml of culture medium were measured. The total activity in the medium
of one well was calculated as the percentage of the total activity determined in plasma membranes from the cells of one well at the zero time point in the absence of glimepiride which was set
at 100% of initial membrane-bound activity. The corresponding specific activities of the medium samples were as follows: 5'-nucleotidase, 1.7 nmol/min per ml; LPL, 24.3 nmol/min per ml; cAMP-
binding, 0.23 pmol/ml. The values represent the means of four different experiments (cell preparations) with triplicate measurements for each. (b) Concentration dependence. 3T3 adipocytes
were incubated for 3 h with different concentrations of glimepiride in the absence (curve A) or presence (curve B) of cycloheximide (150 ,g/ml). Portions of the culture medium were assayed
for 5'-nucleotidase, LPL and cAMP-binding. The total activity recovered in the medium was calculated as the percentage of the initial membrane-bound activity as described above.
Table 1 Specific activities of GPI-anchored and transmembrane plasma-membrane enzymes in the presence or absence of glimepiride
3T3 adipocytes were incubated in the absence or presence of glimepiride (50,M) without or with cycloheximide (150 jug/ml) for 2 h. After removal of the culture medium and washing of the
cells, homogenate and plasma-membrane fractions were prepared. All samples were assayed for 5'-nucleotidase (expressed as nmol/min per mg), LPL (expressed as nmol/min per mg), cAMP-
binding (expressed as pmol/mg), Mg2+-dependent ATPase [expressed as nmol/min per mg or nmol/min per ml (medium)], adenylate cyclase [expressed as pmol/min per mg or pmol/min per
ml (medium)], lactate dehydrogenase [expressed as 1umol/min per mg or umol/min per ml (medium)] and succinate (succ.):cytochrome (cyt.) c oxidoreductase [expressed as nmol/min per mg
or nmol/min per ml (medium)]. The values are means of three different experiments (cell preparations), each with duplicate measurements.
Homogenate Plasma membrane Medium
Control Glimepiride Control Glimepiride Control Glimepiride
5'-Nucleotidase
LPL
cAMP-binding protein
Mg2+-ATPase
Adenylate cyclase
Lactate dehydrogenase
Succ.:cyt. c oxidoreductase
3.5+0.5
1.9+ 0.3
n.d
277 + 38
0.4 + 0.1
38.3 + 4.1
7.9+1.3
2.0 + 0.4
0.6 + 0.2
n.d
298 + 49
0.6 + 0.2
34.5+ 5.0
9.3 + 0.7
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12.7_+1.1
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see Figure 2
see Figure 2
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Figure 3 Glimepiride-induced decrease in the activity of GPI-proteins in the plasma membrane
(a) Time course. 3T3 adipocytes were incubated in the absence (curves B and C) or presence (curves A and D) of glimepiride (50 #M) without (curves A and B) or with (curves C and D) cycloheximide
(150 ug/ml). After the times indicated, the culture medium was removed and the cells were washed and scraped off the plate. Plasma membranes were prepared and assayed for 5'-nucleotidase,
LPL and cAMP-binding protein. The total activity determined in plasma membranes of the cells from one well was calculated as the percentage of the total plasma-membrane activity per well measured
after the zero time point in the absence of glimepiride which was set at 100% of initial membrane-bound activity. The corresponding specific activities of plasma membranes were as follows: 5'-
nucleotidase, 54.5 nmol/min per mg; LPL, 137.4 nmol/min per mg; cAMP-binding, 2.3 pmol/mg. The values represent the means of three different experiments (cell preparations) with triplicate
measurements for each. (b) Concentration-dependence. 3T3 adipocytes were incubated with various concentrations of glimepiride in the absence (thick line) or presence of cycloheximide (150 Ig/ml;
thin line) for 30 min (curves B and C) or 4 h (curve A). 5'-Nucleotidase, LPL (curves D and E) and cAMP-binding (curves F and G) were determined. The total plasma-membrane activity was
calculated as a percentage of the initial membrane-bound activity as described above.
in the activity of the GPI-proteins in the culture medium. For
this the cells were incubated with glimepiride for various times
before the medium was assayed for LPL, 5'-nucleotidase and
cAMP-binding activity. Figure 2(a) shows that the total activities
of all three GPI-proteins increased dramatically in the presence
of glimepiride, but with different time courses, reached a plateau
and, in the case of the LPL and cAMP-binding activity, decreased
thereafter, reaching pretreatment levels after 2-4 h of incubation.
This may be caused by inactivation (proteolysis) or adsorption to
the cell surface (and subsequent endocytosis) of the released
proteins. The loss of LPL activity in the presence of 3T3-LI
adipocytes is well known (Olivercrona and Semb, 1987).
The increase in enzyme activity in the culture medium was
specific for GPI-proteins and not due to leakage of the plasma
membrane, since it was not observed with the transmembrane
plasma-membrane proteins, Mg2+-ATPase and adenylate cyclase,
or the cytosolic and mitochondrial proteins, lactate dehydro-
genase and succinate:cytochrome c oxidoreductase respectively
(Table 1). Control incubations (16 h) with glimepiride (500 ,tM)
demonstrated at least 900% viability of the cells using Trypan
Blue exclusion and overall protein synthesis (metabolic incor-
poration of [35S]methionine into total cellular protein) as criteria
(results not shown).
Interestingly, cycloheximide did not affect the initial increase
but markedly decreased the maximal activity of the three GPI-
proteins in the medium (Figure 2a, curve C). After 3 h of
incubation with both glimepiride and cycloheximide, the activities
fell below the starting values. (Under our experimental con-
ditions, incubation with cycloheximide 10 min before addition of
glimepiride decreased overall protein synthesis by more than
75 %; results not shown.) These observations indicate that the
time-dependent increase in enzyme activity in the medium
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Figure 4 Conversion of GPI-proteins from the amphiphilic into the
hydrophilic form
3T3 adipocytes were metabolically labelled with myo['4C]inositol (a; LPL) or photoaffinity-
labelled with 8-N3-[32P]cAMP (b; cAMP-binding protein). The cells were washed and incubated
in the absence (Control) or presence of glimepiride (50,M) for 30 or 5 min (Chase).
Subsequently, the culture medium (ME) was removed and concentrated by trichloroacetic acid
precipitation (5% trichloroacetic acid, two washes with acetone). The cells were washed and
plasma membranes (PM) were prepared. One-half of the culture medium and plasma
membranes was partitioned into Triton X-1 14 (det) and aqueous (aq) phases; the other half was
left (tot). For identification of LPL, each sample was immunoprecipitated and analysed by
SDS/PAGE and fluorography. For visualization of the photoaffinity-labelled cAMP-binding
protein each samples was applied directly to the gel. Molecular masses were derived from
marker proteins run in parallel on the same gel.
involves both the release from the cell surface, which is in-
dependent of protein synthesis, and synthesis and cell-surface
expression of the GPI-proteins.
The concentration of glimepiride necessary for half-maximal
increase in LPL, 5'-nucleotidase and cAMP-binding activity in
the medium during the initial cycloheximide-insensitive phase
was 7-10 ,tM (Figure 2b), with a maximal effect at 60-75 ,uM,
and is unaffected by cycloheximide. This confirms that the initial
increase in GPI-protein activity in the medium originates from
preformed molecules and not from proteins synthesized de novo
and expressed at the cell surface in response to the drug. However,
stimulation of the expression of GPI-protein genes during long-
term treatment with sulphonylureas, as has been found for
certain glucose-transporter isoforms (Wang et al., 1989;
Tordjman et al., 1989), is not excluded.
If the above hypothesis is true, treatment of cells with
glimepiride in the presence of cycloheximide should result in
depletion of GPI-proteins at the cell surface. To test this, the
total activities of the GPI-proteins in plasma membranes isolated
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0.6
0.4
0.2
E
>
.g0
.)-
0 10 20 30 40 50 60
0 10 20 30 40 50 60 <0
Chase time (min)
Figure 5 Time course for the amphiphilic/hydrophilic conversion of LPL (a)
and cAMP-binding protein (b)
The experiment was carried out as described in the legend to Figure 3 in the absence or
presence of glimepiride (50 ,uM) but with various chase times. Culture medium and plasma
membranes were subjected to Triton X-1 14 partitioning. The aqueous phase recovered from the
culture medium (curve A) and the detergent phase recovered from plasma-membrane samples
(curve B) were analysed after immunoprecipitation (LPL) or directly (cAMP-binding protein) by
SDS/PAGE and densitometry of the fluorogram. The ratio between the densitometric values for
the plasma membrane (amphiphilic version) or culture medium (hydrophilic version) respectively,
in the presence or absence of glimepiride, was calculated for each time point. For the zero time
point this ratio was set at 1.0 (fraction of initial value of the plasma membrane and medium
respectively). Each value represents the means of three different experiments using different cell
preparations.
from glimepiride-stimulated 3T3 adipocytes were determined.
The method used for the fractionation of the cultured fat cells
yielded plasma membranes of sufficient purity, as demonstrated
by an up to 10-fold enrichment in the plasma-membrane proteins,
adenylate cyclase and Mg2+-ATPase, together with the GPI-
proteins, and the diminution of mitochondrial and cytosolic
proteins (Table 1). Figure 3(a) shows that, in the absence of
cycloheximide, glimepiride provoked an initial rapid decrease in
plasma medium activity of each GPI-protein followed by a rapid
increase, finally reaching pretreatment or even higher levels. In
the absence of glimepiride the specific activities remained
constant. However, the presence of cycloheximide caused a
prolonged phase of decrease in the plasma-membrane activity
and inhibited its recovery. Incubation with cycloheximide alone
caused a slight decrease in activity during the entire incubation
period, indicating a basal turnover (degradation and/or release)
of the GPI-proteins studied. The altered distribution of GPI-
protein but not of integral membrane protein activity (Table 1)
again emphasizes the selectivity of the sulphonylurea-stimulated
releasing process.
The drug concentrations required for maximal loss of GPI-
protein activity in the plasma membrane were in the range
3-8 ,uM (Figure 3b, thick lines). Cycloheximide had only minor
effects (Figure 3b, thin lines) in agreement with the acute effects
of glimepiride. However, after long-term incubation with any
concentration of glimepiride, pretreatment levels of plasma-
membrane activity were measured in the absence of cyclo-
heximide (shown only for 5'-nucleotidase in Figure 3b), indicating
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Figure 6 Identffication of inositol as a component of cellular and released GPI-proteins
3T3 adipocytes were metabolically labelled with myo[14C]inositol and incubated in the absence or presence of 50 uM glimepiride for the times indicated or with 0.25 unit of PI-PLC (Bacillus
cereus) per well for 2 h at 37 °C. The culture medium was removed and plasma membranes were prepared from the cells. Equivalent volumes of medium and amounts of membranes were
immunoprecipitated with anti-LPL serum or affinity-purified by cAMP-Sepharose chromatography. The radiolabelled immunoprecipitated LPL or affinity-purified cAMP-binding protein was separated
by SDS/PAGE, eluted from sliced gel pieces and dried under N2. The plasma-membrane samples were resuspended in 0.5 ml of 4 M HCI and incubated at 10O°C for 5 h. The total HCI hydrolysates
were applied directly on to a t.I.c. plate which was fluorographed (a, lane 1) and scanned for radioactivity (Berthold radioactivity scanner) (b). The radioactivity of the total hydrolysate applied (total)
and of the spot co-migrating with the myoinositol marker (a, I) are given (b, I). The medium samples were concentrated by evaporation (speedvac), subjected to nitrous acid deamination (NA)
and subsequently precipitated with 5% trichloroacetic acid (4 OC, 1 h, then 10000 g, 5 min, two acetone washes). The pellet was dissolved in scintillation cocktail and counted for radioactivity
(b, protein). The supernatant was neutralized, concentrated by freeze-drying and analysed by t.l.c. and fluorography (a, lanes 2-6). The radioactivity of the spot co-migrating with the myo-inositol
phosphate marker (a, IP) was determined by liquid-scintillation counting of the corresponding spot material scraped from the plate (b, IP). As a control, an equivalent volume of the deaminated
incubation mixture (30 min glimepiride; a, lane 6) was hydrolysed with 4 M HCI at 110 nC for 5 h after freeze-drying before t.I.c. analysis and fluorography (a, lane 7). 14C_labelled myo-inositol
(1), myo-inositol 1-phosphate (IP) and phosphatidylinositol (PI) were run in parallel as markers. Their positions and the origin (o) and front (f) are indicated on the right margin.
a steady state between synthesis/cell surface expression and
release of the GPI-protein.
The correlation between the initial phase of GPI-protein
activity loss in the plasma membrane and appearance in the
culture medium strongly suggests release of the GPI-proteins
from the plasma membrane in response to the sulphonylurea
drug. To demonstrate this directly, cells were metabolically
labelled with myo-[14C]inositol or photoaffinity-labelled with 8-
N3-[32P]cAMP and subsequently incubated for various times in
the absence or presence ofglimepiride with an excess ofunlabelled
myo-inositol or cAMP respectively. The medium and plasma
membranes were analysed for membrane-bound and released
radiolabelled proteins by their partitioning behaviour between a
detergent (Triton X-1 14) and an aqueous phase. LPL (60 kDa)
was identified by immunoprecipitation with a polyclonal anti-
body against human milk LPL (the specificity of the antibody
has been established) whereas the cAMP-binding ectoprotein
was visualized by photoaffinity labelling with 8-N3-[32P]cAMP as
a single band (62 kDa) in the plasma-membrane fraction
(G. Muller and W. Bandlow, unpublished work).
Figure 4 shows that, after 30 min of incubation in the absence
of glimepiride, most of the LPL and cAMP-binding protein was
localized at the plasma membrane (lane 1) and partitioned into
the detergent phase (lane 2). Only a minor portion was detectable
in the medium (lane 5) which may originate from broken cells. In
contrast, in the presence of glimepiride the majority of both LPL
and cAMP-binding protein was recovered from the medium
(lane 10), most of which partitioned into the aqueous phase (lane
12). Intermediary levels of plasma-membrane-bound (lane 13),
amphiphilic (lane 14) and soluble (lane 16), hydrophilic (lane 18)
radiolabelled GPI-proteins were observed after a 5 min chase
with glimepiride. The ratio, however, differed with the protein
studied.
The kinetics of the decline in amphiphilic and increase in
hydrophilic LPL and cAMP-binding protein were in close
correlation (expressed as a ratio in the presence or absence of
glimepiride) during 60 min of chase (see quantification in Figure
5). For up to 40 min the sum of the radiolabelled amphiphilic
and hydrophilic versions remained nearly constant. Longer chase
times markedly decreased the recovery, possibly as a result of
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Figure 7 Retention of myo-inositol and anti-CRO immunoreactivity in GPI-proteins released from 3T3 adipocytes by glimepiride
(a) 3T3 adipocytes were metabolically labelled with myo_[14C]inositol and [14C]leucine and subsequently incubated in the absence or presence of 50 itM glimepiride for the times indicated. The
culture medium was removed and plasma membranes were prepared from the cells. Equivalent volumes of the medium and membranes were subjected to Triton X-1 14 partitioning and subsequent
immunoprecipitation with anti-LPL serum or affinity purification with cAMP-Sepharose chromatography. The immunoprecipitates (LPL, upper gels) or affinity-purified material (cAMP-binding protein,
lower gels) of the detergent phase of the membrane samples (d) and of the aqueous phase of the medium samples (a) respectively were analysed by SDS/PAGE and fluorography. Similar d.p.m.
values of [14C]leucine- and myo-inositol-labelled protein were applied. The molecular masses were derived from metabolically labelled and immunoprecipitated LPL (60 kDa) and photoaffinity-labelled
cAMP-binding protein (62 kDa) from adipocyte homogenate run in parallel. (b) The anti-LPL immunoprecipitates and affinity-purified material (amounts identical with a) were immunoprecipitated
with anti-CRD antibodies and analysed by SDS/PAGE and fluorography. (c) 3T3 adipocytes were metabolically labelled with myo_[14C]inositol (LPL, cAMP-binding protein; curves B and D) and
[3H]leucine (LPL; curves A and C), or alternatively were photoaffinity-labelled with 8-N3-[3H]cAMP (cAMP-binding protein; curves A and C), and subsequently incubated with 50 1uM glimepiride
for the times indicated. Samples of the culture medium were subjected to immunoprecipitation with anti-LPL serum (LPL) or trichloroacetic acid precipitation (cAMP-binding protein). One-half of
the immunoprecipitates and trichloroacetate-precipitated material was analysed by SDS/PAGE, directly (curves A and B), the other half after immunoprecipitation with anti-CRD antibodies (curves
C and D). The 3H (curves A and C) and 14C (curves B and D) radioactivities of total and anti-CRD immunoreactive LPL and cAMP-binding protein were measured with a Berthold scanner. The
3H and 14C radioactivities of total cellular immunoprecipitated LPL or affinity-purified cAMP-binding protein at time 0 were set at 100% each.
degradation of the soluble forms. The presence of cycloheximide
did not affect the kinetics of the conversion up to 30 min of chase
(results not shown). The amphiphilic/hydrophilic transition of
the GPI-proteins can be best explained by proteolytic or lipolytic
removal of the GPI moiety causing release of the protein from
the outer face of the plasma membrane of 3T3 adipocytes into
the medium.
The retention of radioactivity in the LPL and cAMP-binding
ectoprotein from 3T3 adipocytes metabolically labelled with
myo-[14C]inositol for 14 h represents a first indication for a
lipolytic cleavage event. Under these conditions most of the
radioactivity of LPL and cAMP-binding protein was recovered
in the inositol residue after total acid hydrolysis of the purified
proteins, t.l.c. analysis and fluorography (Figure 6a, lane 1) or
liquid-scintillation counting of the material co-migrating with
the inositol marker (Figure 6b, HCl treatment). This is in
agreement with the finding that the protein moiety of LPL and
cAMP-binding ectoprotein prepared by nitrous acid deamination
(which specifically cleaves between the inositol and non-
acetylated glucosamine residues) instead of acid hydrolysis and
subsequent trichloroacetic acid precipitation contained very little
radioactivity (Figure 6b, protein).
We next studied whether the myo-["4C]inositol moiety of LPL
and cAMP-binding protein is retained quantitatively in the
protein moiety after membrane release of the GPI-proteins by
glimepiride. Cells were metabolically labelled in parallel with
myo-[14C]inositol or ['4C]leucine and incubated with glimepiride
for various times. The GPIL-proteins were purified from the
plasma membrane and culture medium by Triton X- 114 par-
titioning, immunoprecipitation (LPL) or affinity chromato-
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Figure 8 Effect of glimepiride on the insulin-stimulated release of GPI-
proteins
3T3 adipocytes were incubated for 30 min in the absence (curve A) or presence of 5 ,uM (curve
B) or 50 uM (curve C) glimepiride with various concentrations of insulin. 5'-Nucleotidase and
LPL in the culture medium were assayed as described in the legend to Figure 1 (a). Each point
represents the means of three different experiments (cell preparations) with duplicate
measurements for each.
graphy (cAMP-binding protein) and SDS/PAGE. The
fluorogram (Figure 7a) shows that the increase in the amount of
the [x4C]leucine-labelled hydrophilic form of both GPI-proteins
in the medium throughout 30 min of incubation (lanes 3, 5, 7, 17,
19 and 21) was paralleled by a decrease in the amphiphilic form
in the plasma membrane (lanes 2, 4, 6, 16, 18 and 20). The
decrease was also observed for the [x4C]inositol-labelled GPI-
proteins (lanes 8, 10, 12, 22, 24 and 26). In contrast, the kinetics
of appearance of their hydrophilic versions reached a plateau
after 15 min incubation with glimepiride (lanes 11, 13, 25 and
27), indicating the emergence of a portion of released molecules
lacking inositol. The presence of a terminal inositol residue was
confirmed by immunoprecipitation of a portion of the same
material with anti-CRD antibodies (Figure 7b). The time course
of immunoreactivity of the hydrophilic LPL and cAMP-binding
protein correlated well with the myo-inositol (lanes 10, 12, 14, 26,
28 and 30) but not with the leucine label (lanes 4, 6, 8, 20, 22 and
24). The amphiphilic versions did not react with the anti-CRD
antibodies to a significant extent demonstrating their high
specificity. Only small amounts of hydrophilic total (Figure 7a,
lanes 1, 14, 15 and 28) and immunoreactive (Figure lb, lanes 2,
16, 18 and 32) GPI-proteins were observed after incubation for
30 min in the absence of glimepiride.
For quantification of the portion of released GPI-proteins
without inositol, double labelling experiments with myo-
[14C]inositol and [3H]leucine (LPL) or myo_[u4C]inositol and 8-
N3-[3H]cAMP (cAMP-binding protein) were performed. After
metabolic labelling, photoaffinity labelling and incubation of
3T3 adipocytes with glimepiride, LPL and the cAMP-binding
ectoprotein recovered from the culture medium were
immunoprecipitated and affinity-purified respectively, and
Table 2 Release of GPI-proteins pretreated with cholera-and pertussis
toxins or proteinase inhibitors
3T3 adipocytes were pretreated as follows: (1) with cholera toxin (CT, 200 ng/ml) or pertussis
toxin (PT, 100 ng/ml) for 20 h before addition of glimepiride, (2) with a2-macroglobulin (MG,
1 mM), 4-(2-aminoethyl)benzylsulphonyl fluoride (ABF, 100 ,uM) or a mixture of leupeptin,
pepstatin A and antipain dihydrochloride (each 10 ,tg/ml) for 5 min before addition of
glimepiride, or (3) mock-treated for 20 h before glimepiride stimulation, and then incubated in
the absence or presence of glimepiride (Gli; 50 ,uM) for 30 min. LPL and cAMP-binding protein
in the culture medium and plasma membrane were assayed as described in legend to Figure
1(a). The values represent the means+ S.D. of three different experiments (celt preparations
and pretreatments), each with triplicate determinations.
LPL cAMP-binding protein
Plasma Plasma
Treatment Medium membrane Medium membrane
- 1 1 1 1
Gli 2.22 + 0.35 0.53 + 0.12 4.38+ 0.66 0.36 + 0.08
PT+Gli 2.01 +0.28 0.60+0.17 4.71 +0.81 0.25+0.06
CT+Gli 2.43+0.50 0.41 +0.09 4.55+0.53 0.44+0.09
MG + Gli 2.68 + 0.43 0.38+ 0.11 4.24 + 0.70 0.31 + 0.10
PF+ Gli 2.11 + 0.31 0.51 + 0.17 4.02 + 0.86 0.45+ 0.14
Mix+Gli 2.07+0.28 0.45+0.10 3.97+0.49 0.51 +0.12
analysed by SDS/PAGE directly or after immunoprecipitation
with anti-CRD antibodies. The gels were scanned for 3H/14C
radioactivity. Figure 7(c) shows that for both the LPL and
cAMP-binding protein the 3H and 14C radioactivity increased
together with the anti-CRD immunoreactivity up to 15 min of
incubation resulting in a constant ratio of total and anti-CRD
immunoreactive 3H/14C. Thereafter total and immunoreactive
14C radioactivity remained constant with a decrease in the
absolute values, whereas the amount of released total, but not
immunoreactive 3H-labelled LPL and cAMP-binding protein,
increased further. Taken together, the identification of soluble
GPI-proteins containing myo-inositol and exhibiting anti-CRD
immunoreactivity strongly suggests that glimepiride causes rapid
release of some GPI-proteins by lipolytic cleavage of their GPI
membrane anchor. With longer incubation times, a portion of
the released GPI-proteins lacks terminal myo-inositol as a result
of hydrolytic cleavage(s) either within the glycosidic, phospho-
diester or amide bonds of the GPI structure or proteolysis at the
C-terminus. If the latter is the case, the proteinase involved
should not be affected by a variety of proteinase inhibitors. No
effect of a2-macroglobulin, 4-(2-aminoethyl)benzylsulphonyl
fluoride, leupeptin, pepstatin A or antipain dihydrochloride on
glimepiride-induced release of LPL and cAMP-binding ecto-
protein was detected (Table 2).
To identify the cleavage site of the putative phospholipase that
acts during the initial phase of the releasing process, myo-
[x4C]inositol-labelled LPL and cAMP-binding protein were
isolated from the culture medium of 3T3 adipocytes after
incubation with glimepiride and then subjected to nitrous acid
deamination (Figure 6). After precipitation ofthe released protein
moiety with trichloroacetic acid, the supernatant was analysed
by t.l.c., fluorography (Figure 6a) and liquid-scintillation
counting of the radiolabelled spot material (Figure 6b). The
amount of the spot co-migrating with the inositol 1-phosphate
marker (Figure 6a, IP) increased with the incubation time (Figure
6a, lanes 3-6; Figure 6b, IP). The nature of this material (30 min
incubation) was confirmed by total acid hydrolysis which almost
completely converted inositol phosphate into inositol (Figure 6a,
lane 7). The marginal amount of radiolabelled inositol detected
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Figure 9 Effect of long-term treatment with glimepiride on release of GPI-proteins
0.5 5 50 500
5
[Glimepiride] (,M)
3T3 adipocytes were preincubated in the absence (curve A) or presence (curve B) of glimepiride (50 ,uM) for 16 h. Subsequently the cells were washed three times with DMEM and incubated
in the absence or presence of various concentrations of insulin (a) or glimepiride (b) for 30 min. 5'-Nucleotidase and LPL in the culture medium were assayed as described in the legend to Figure
1 (a).
after incubation with glimepiride may be due to phosphatase
action in the culture medium or during isolation of the proteins.
The identification of inositol phosphate in the released GPI-
proteins, as was observed after a control incubation of 3T3
adipocytes with bacterial PI-PLC (Figure 6a, lane 2), indicates
the activation of a GPI-PLC by glimepiride in 3T3 adipocytes.
The generation of radiolabelled phosphatidylinositol after
incomplete digestion of the GPI-proteins by PI-PLC and
glimepiride (Figure 6a, lanes 2-6) again confirmed the metabolic
incorporation of myo-[14C]inositol.
Since some bacterial toxins are known to interfere with
hormone-stimulated PLC action, we investigated the effect of
Bordetella pertussis and Vibrio cholerae toxins on glimepiride-
induced release of the GPI-proteins. Pretreatment of 3T3
adipocytes with both toxins did not affect basal or drug-induced
specific activities of the LPL or cAMP-binding protein in the
plasma membranes or culture medium (Table 2). Under the same
conditions, pertussis toxin blocked the early insulin-stimulated
generation of dimyristoylglycerol (results not shown). Thus the
release of these GPI-proteins does not seem to be catalysed by
PLC which is regulated via pertussis or cholera toxin-sensitive G-
proteins.
In addition to sulphonylurea agents, shown in this study,
insulin has been reported to stimulate release of several GPI-
proteins from 3T3-Ll adipocytes by degradation of their GPI
membrane anchor 4,see the Discussion). Therefore we were
interested in the relationship between the drug- and insulin-
induced membrane-releasing mechanisms. Cells were incubated
with either 5 or 50 ,uM glimepiride in combination with increasing
concentrations of insulin (0.1-100 nM) before the medium was
assayed for LPL and 5'-nucleotidase (Figure 8). Glimepiride at
both concentrations caused a significant increase in enzyme
activity in the medium compared with insulin stimulation alone
(Figure 8, curve A). At 5 ,uM glimepiride and 1-20 nM insulin,
the total release (Figure 8, curve B) exceeded the sum of the
insulin and glimepiride effects alone, indicative of synergistic
effects of glimepiride and insulin. At 50SM glimepiride and
insulin below 10 nM, the effects of glimepiride and insulin were
additive, and, with insulin above 10 nM, they were non-additive.
The synergistic release at low and the non-additive release at high
concentrations of glimepiride and insulin represent a first clue
that the sulphonylurea drug and insulin use at least one common
step for membrane release of GPI-proteins.
Chronic treatment with sulphonylurea drugs has been reported
to increase insulin sensitivity in vivo and in vitro (see the
Introduction). Therefore we investigated whether long-term
incubation of 3T3 adipocytes with glimepiride enhances the
insulin-stimulated release of LPL and 5'-nucleotidase (Figure 9).
To this end, 3T3 adipocytes were incubated with glimepiride
(50 ,uM) for 16 h, then washed extensively to remove the drug
and already released GPI-proteins and subsequently treated with
various concentrations of insulin (Figure 9a) for 30 min after
which the specific activities of LPL and 5'-nucleotidase in the
culture medium were assayed. Long-term incubation with
glimepiride (Figure 9a, curve B) resulted in a significant leftward-
shift of the dose-response curve for subsequent acute stimulation
ofmembrane release of the GPI-proteins by insulin. The maximal
rate of release was not increased significantly. Analogously,
long-term treatment with glimepiride increased the sensitivity of
the GPI-protein release for glimepiride (Figure 9b). Interestingly,
pretreatment with glimepiride caused a marked release of LPL
and 5'-nucleotidase during the subsequent 30 min of incubation
in the absence of insulin (Figure 9a) or glimepiride (Figure 9b).
Thus either glimepiride was not removed completely before the
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short-term treatment or the releasing mechanism, once activated
by the drug, persists for a prolonged period of time.
DISCUSSION
This paper demonstrates that the novel sulphonylurea drug,
glimepiride, stimulates the release of three ectoproteins, LPL, 5'-
nucleotidase and a 62 kDa cAMP-binding protein, from the
plasma membrane of 3T3 adipocytes into the culture medium.
This is based on the time- and concentration-dependent increase
in the enzyme activity of these proteins in the medium ac-
companied by a parallel decrease in enzyme activity in the
plasma membrane. Furthermore, radiolabelled LPL and cAMP-
binding protein are converted from the membrane-bound
amphiphilic form into the soluble hydrophilic form during
incubation with glimepiride.
It is possible that the sulphonylurea- and insulin-dependent
releasing mechanisms share some common steps, since at
submaximal concentrations the two agents act in a synergistic
manner and at higher concentrations they do not exceed a
maximal level of release. Up until now, insulin-regulated mem-
brane release of GPI-proteins has been reported for 3T3-LI
adipocytes [LPL (Eckel et al., 1978; Spooner et al., 1979; Chan
et al., 1988); several unidentified proteins (Lisanti et al., 1989);
5'-nucleotidase and cAMP-binding ectoprotein (this study)],
BC3H1 myocytes [alkaline phosphatase (Romero et al., 1988)]
and HepG-2 cells [heparan sulphate proteoglycan (Ishihara et
al., 1987)], for membranes prepared from rat hindquarter muscles
after perifusion with insulin [5'-nucleotidase (Klip et al., 1988)]
and for rat osteosarcoma cells after culture in the presence of
insulin [alkaline phosphatase (Levy et al., 1984)].
The retention of myo-inositol phosphate and appearance of
anti-CRD cross-reactivity in the soluble GPI-proteins during the
initial phase of glimepiride-induced release indicate cleavage of
the GPI membrane anchor by GPI-PLC. Degradation of the PI
anchor has also been suggested for the insulin-stimulated release
of LPL (Chan et al., 1988). However, the appearance of released
(and enzymically active) LPL and cAMP-binding ectoprotein
without myo-inositol and anti-CRD immunoreactivity during
later stages of incubation hints at additional hydrolytic processing
near the GPI attachment site which does not decrease the
apparent size of the proteins in SDS/PAGE. These molecules
may originate from either membrane-anchored or lipolytically
released GPI-proteins. The kinetics of their appearance after a
large pool of lipolytically released proteins has accumulated
suggests the latter possibility, i.e. two sequential distinct lipolytic
and hydrolytic processing events.
The mechanism by which sulphonylurea drugs stimulate the
GPI-PLC remains to be elucidated. A sulphonylurea receptor
has been described in pancreatic ,-cells and the brain (Kramer et
al., 1988) and characterized as a putative component of an ATP-
dependent K+ channel [for a review see Boyd (1988)] which,
however, is absent from 3T3-LI adipocytes and BC3Hl and L6
myocytes (Rajan and Boyd, 1988; Cooper et al., 1990; Davidson
et al., 1991). Binding studies indicate the existence also of specific
sulphonylurea receptors in isolated rat adipocytes (Martz et al.,
1989). They have not been characterized so far, but may form a
component of the signal-transduction cascade through which
sulphonylurea drugs activate a GPI-PLC in extrapancreatic
insulin-sensitive cells. It is unknown whether this PLC is struc-
turally related to the insulin-stimulated GPI-PLC from rat liver
membranes (Saltiel and Cuatrecasas, 1986; Saltiel et al., 1986),
the only GPI-PLC in mammalian cells described so far.
The functional significance of the regulated release of GPI-
ectoproteins from the plasma membrane remains a matter of
speculation. It may represent a means to down-regulate the cell
surface expression of these proteins with respect to their turnover
or reduced requirement during some physiological situation.
Alternatively, the activity of tne GPI-proteins released into the
extracellular space per se may be of physiological importance.
The functional state and role of solubilized GPI-proteins in
extracellular fluids is not completely understood [for a review see
Low (1987) and Low and Saltiel (1988)]. LPL released from
parenchymal cells of various tissues moves through the vascular
endothelium and binds to the capillary luminal surface where it
hydrolyses di- and tri-acylglycerols. The insulin-deficient state
(during uncontrolled type I diabetes) is accompanied by low
plasma LPL activity and hypertriglyceridaemia (Bagdade et al.,
1967), pointing to a special need for soluble LPL. Although the
function of the cAMP-binding ectoproteins, recently identified
in lower and higher eukaryotes, is not known, it may be of
interest in this respect that the yeast GPI-anchored 54 kDa
cAMP-binding ectoprotein, which is structurally related to
the cAMP-binding ectoprotein of 3T3 adipocytes, exhibits
different cAMP-binding characteristics and an additional amino
acid photoaffinity-labelled with 8-N3-[32P]cAMP after cleavage
of its GPI membrane anchor with exogenous GPI-PLC from
Trypanosoma brucei (G. Muller and W. Bandlow, unpublished
work). This hints at the possibility that the removal of the GPI
modification and/or the altered localization may cause changes
in the conformation and function of GPI-proteins. A physio-
logical function may also reside in the potential cleavage products
of PLC action on the GPI moiety and limited proteolysis at the
C-terminus of the GPI-proteins, diacylglycerol and GPI-peptides
or phosphoinositolglycan peptides. These molecules may func-
tion as chemical mediators for some of the stimulatory effects of
sulphonylurea on glucose utilization in isolated rat adipocytes
and cultured 3T3-LI adipocytes (Jacobs et al., 1989; Farese et
al., 1991).
Our data imply that the novel sulphonylurea compound,
glimepiride, is not only valuable as an oral antidiabetic drug
(Geisen, 1988), but may be useful for elucidation of the mode
of action of this class of therapeutic agents in extrapancreatic
tissues.
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